ArticleScientific reports2025
Nanotechnology Meets superbugs: biocompatible polymeric nanoparticles combat MDR Klebsiella pneumoniae via gene suppression and biofilm Inhibition.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pre-Target Interception Defines Carbapenem Failure in Carbapenem-Resistant Enterobacterales: A Mechanistic Framework for Spatiotemporal Drug Reprogramming.Pharmaceutics · 2026Review
- Expanding the Antimicrobial Toolbox with Therapeutic Viruses: Mechanisms, Pharmaceutical Formulation, and Translational Outlook.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem-resistant Klebsiella pneumoniae (CRKP) is a critical threat in healthcare settings due to its limited treatment options and high resistance to conventional antibiotics. This study explores the potential of polycaprolactone (PCL) nanospheres as a delivery vehicle for imipenem to combat multidrug-resistant CRKP. Imipenem-loaded nanospheres, with an average size of 610 ± 125 nm and an encapsulation efficiency of 84.5%, were synthesized using a double-emulsion method and characterized for morphology, size, drug loading, and release profile. The formulation demonstrated a substantial improvement in antibacterial activity, with an eightfold reduction in minimum inhibitory concentration compared to free imipenem. The nanoparticles also significantly inhibited biofilm formation and accelerated bacterial killing. Molecular analysis showed marked suppression of key resistance genes. Additionally, cytotoxicity assays confirmed high biocompatibility, with over 80% viability in fibroblast cells. These findings indicate that PCL-based nanocarriers enhance the efficacy and safety profile of imipenem, offering a promising strategy for addressing antibiotic resistance in CRKP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.